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Adoptive cell therapy (ACT) with tumor-infiltrating lym-
phocytes (TILs) has shown promising results in early
phase trials. In an approach developed by the Rosenberg
group at the Surgery Branch (NCI), patients with meta-
static melanoma receive a pre-conditioning regimen of
cyclophosphamide and fludarabine-induced lymphodeple-
tion (+/- total body irradiation), followed by infusion of
autologous TILs and high-dose interleukin-2 (IL-2) ther-
apy. At our institution, we have established the technology
to produce therapeutic-grade TILs. Our preclinical work
included adapting protocols from the Surgery Branch to
expand TILs from melanoma lesions, setting up a program
to obtain blood products from healthy donors to support
the in vitro expansion of TILs, and establishing Standard
Operating Procedures for production of therapeutic-grade
TILs. In order to generate sufficient numbers of cells for
infusion, TILs are subjected to a “Rapid Expansion Proto-
col” (REP) using anti-CD3 antibody (OKT3), feeder cells
(irradiated peripheral blood mononuclear cells) and inter-
leukin-2. In our preclinical work, we found that the REP
could be performed using concentrations of IL-2 that are
lower than those usually used: 300 and 600 IU/ml of IL-2
induced similar fold-expansion and CD4:CD8 ratios as
3000 IU/ml of IL-2. Survival of TILs in vitro after the REP
in various concentrations of IL-2 was also assessed. We
reasoned that TILs that had been rapidly expanded in a
lower concentration of IL-2 would subsequently not
require high-dose IL-2 after infusion in order to mediate
clinical responses. If this is the case, use of a lower dose of
IL-2 therapy for TIL protocols would improve the toxicity
profile of ACT and reduce resources needed for inpatient
care. In order to explore this hypothesis, we have designed
a clinical trial of cyclophosphamide and fludarabine fol-
lowed by TIL infusion and an intermediate dose of IL-2
therapy (125,000 IU/kg for 2 weeks with 2 days rest in
between each week). Institutional and federal regulatory
approvals have been obtained for this trial.
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